Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy)

The assay of cardiac-specific troponins (cTroponins) is a sensitive and specific means to diagnose myocardial injury. Several assays for the measurement of cardiac-specific troponin I (cTnI), but only 1 for the assay of cardiac specific troponin T (cTnT), are commercially available. The aim of this...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2002-05, Vol.89 (9), p.1035-1041
Main Authors: Venge, Per, Lagerqvist, B.o, Diderholm, Erik, Lindahl, Bertil, Wallentin, Lars
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
Cardiology. Vascular system
Cardiovascular disease
Cohort Studies
Comparative Study
Coronary Arteriosclerosis/blood/diagnosis/therapy
Coronary Artery Disease - blood
Coronary Artery Disease - diagnosis
Coronary Artery Disease - therapy
Coronary heart disease
Disease Progression
Female
Heart
Humans
Male
Medical research
Medical sciences
Predictive Value of Tests
Prospective Studies
Protein Isoforms - blood
Regression Analysis
Reproducibility of Results
Sensitivity and Specificity
Survival Rate
Troponin - blood
Troponin I - blood
Troponin T - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The assay of cardiac-specific troponins (cTroponins) is a sensitive and specific means to diagnose myocardial injury. Several assays for the measurement of cardiac-specific troponin I (cTnI), but only 1 for the assay of cardiac specific troponin T (cTnT), are commercially available. The aim of this study was to compare 3 of these assays (i.e., Access AccuTnI [cTnI], AxSym [cTnI], and Elecsys 3 rd generation [cTnI]) and their clinical performances in a group of patients (n = 1,763) with unstable coronary artery disease (Fragmin and fast Revascularisation during InStability in Coronary artery disease [FRISC II] trial). Clinical events after 1-year follow-up, such as death and death and/or acute myocardial infarction, were recorded and the effects of invasive or noninvasive treatment evaluated in relation to cTroponin levels. Overall the 2 cTnI methods showed good correlation (r s = 0.96), whereas correlations to the cTnT assay were somewhat lower (r s = 0.93). Patients with nonelevated levels, as measured with any of the 3 biomarkers, had a significantly better prognosis than patients with elevated levels (p
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(02)02271-3